LENSAR

LENSAR ROE

The Return on Equity (ROE) of LENSAR (LNSR) as of Oct 20, 2026 is 131.75 %. In the previous year, Return on Equity (ROE) was -168.42 % — a change of -178.23% (higher).

ROE

131.75 %

YoY

-178.23%

Last updated:

In 2025, LENSAR's return on equity (ROE) was 131.75 %, a -178.23% increase from the -168.42 % ROE in the previous year.

The LENSAR ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
61.53 USD
Jan 1, 2019
47.97 USD
Jan 1, 2020
-29.42 USD
Jan 1, 2021
-35.72 USD
Jan 1, 2022
-47.43 USD
Jan 1, 2023
-30.49 USD
Jan 1, 2024
-168.42 USD
Jan 1, 2025
131.75 USD
The LENSAR ROE history
YEARROEYoY
131.75 %-178.23%
-168.42 %+452.42%
-30.49 %-35.72%
-47.43 %+32.80%
-35.72 %+21.40%
-29.42 %-161.33%
47.97 %-22.04%
61.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR, Inc. generates revenue through the sale of its femtosecond laser systems, specifically the LENSAR Laser System with Streamline IV and IntelliAxis, and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System includes disposable patient interface device kits as consumables, which contribute to recurring revenue. Surgeons and ophthalmic clinics purchasing these systems form the primary customer segment, utilizing the technology for cataract surgery and corneal astigmatism management. The company's focus on proprietary technologies ensures differentiation in the medical device market. The ALLY System is marketed as a compact solution for femtosecond laser assisted cataract procedures, designed to streamline surgical workflows within a single operating room. Its product portfolio emphasizes integrated features that enhance visual outcomes for patients. The consumable components, such as the disposable patient interface device kits, support ongoing revenue streams alongside the initial system sales. These offerings target healthcare providers seeking advanced surgical tools for refractive cataract surgery. LENSAR's business model relies on selling high-precision medical devices to specialized healthcare facilities. The LENSAR Laser System and ALLY System are positioned as premium solutions for cataract treatment, with the consumables providing sustained revenue opportunities. The company's product development centers around improving surgical efficiency and patient visual results through its patented technologies. LENSAR is one of the most popular companies on Eulerpool.

ROE Details

Decoding LENSAR's Return on Equity (ROE)

LENSAR's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing LENSAR's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

LENSAR's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in LENSAR’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about LENSAR stock

Return on Equity (ROE) of LENSAR is 131.75 % in 2025.

Return on Equity (ROE) of LENSAR changed from -168.42 % to 131.75 %, representing a -178.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) LENSAR since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — LENSAR

All Key Metrics — LENSAR